Compare VIP & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIP | GRDX |
|---|---|---|
| Founded | 1937 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 28.6M |
| IPO Year | 2021 | 2016 |
| Metric | VIP | GRDX |
|---|---|---|
| Price | $0.96 | $4.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 64.5K | ★ 107.1K |
| Earning Date | 11-20-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.09 | 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,388,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $1.87 |
| 52 Week High | $2.74 | $6.93 |
| Indicator | VIP | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 19.59 | 51.39 |
| Support Level | N/A | $2.35 |
| Resistance Level | $1.36 | $5.04 |
| Average True Range (ATR) | 0.08 | 0.61 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 6.22 | 34.26 |
Vulcan Infrastructure and Power Inc is a power and infrastructure platform focused on acquiring, developing and operating energized sites that support artificial intelligence and high-performance computing data centers, as well as local electricity grids.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.